Neomycin microbiology: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 5: | Line 5: | ||
==Microbiology== | ==Microbiology== | ||
In vitro tests have demonstrated that neomycin is bactericidal and acts by inhibiting the synthesis of protein in susceptible bacterial cells. It is effective primarily against [[gram-negative]] bacilli but does have some activity against [[gram-positive]] organisms. Neomycin is active in vitro against [[Escherichia coli]] and the [[Klebsiella]]-[[Enterobacter]] group. Neomycin is not active against anaerobic bowel flora. | In vitro tests have demonstrated that neomycin is bactericidal and acts by inhibiting the synthesis of protein in susceptible bacterial cells. It is effective primarily against [[gram-negative]] bacilli but does have some activity against [[gram-positive]] organisms. Neomycin is active in vitro against [[Escherichia coli]] and the [[Klebsiella]]-[[Enterobacter]] group. Neomycin is not active against [[anaerobic]] bowel flora. | ||
If susceptibility testing is needed, using a 30 mcg disc, organisms producing zones of 16 mm or greater are considered susceptible. Resistant organisms produce zones of 13 mm or less. Zones greater than 13 mm and less than 16 mm indicate intermediate susceptibility.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | If susceptibility testing is needed, using a 30 mcg disc, organisms producing zones of 16 mm or greater are considered susceptible. Resistant organisms produce zones of 13 mm or less. Zones greater than 13 mm and less than 16 mm indicate intermediate susceptibility.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | ||
Latest revision as of 17:12, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Microbiology
In vitro tests have demonstrated that neomycin is bactericidal and acts by inhibiting the synthesis of protein in susceptible bacterial cells. It is effective primarily against gram-negative bacilli but does have some activity against gram-positive organisms. Neomycin is active in vitro against Escherichia coli and the Klebsiella-Enterobacter group. Neomycin is not active against anaerobic bowel flora.
If susceptibility testing is needed, using a 30 mcg disc, organisms producing zones of 16 mm or greater are considered susceptible. Resistant organisms produce zones of 13 mm or less. Zones greater than 13 mm and less than 16 mm indicate intermediate susceptibility.[1]
References
Adapted from the FDA Package Insert.